YU49060B - FARMACEUTSKE KOMPOZICIJE KOJE SADRŽE INHIBITOR BIOSINTEZE HOLESTEROLA I INHIBITIR APSORPCIJE Гџ-LAKTAM HOLESTEROLA - Google Patents

FARMACEUTSKE KOMPOZICIJE KOJE SADRŽE INHIBITOR BIOSINTEZE HOLESTEROLA I INHIBITIR APSORPCIJE Гџ-LAKTAM HOLESTEROLA

Info

Publication number
YU49060B
YU49060B YU80293A YU80293A YU49060B YU 49060 B YU49060 B YU 49060B YU 80293 A YU80293 A YU 80293A YU 80293 A YU80293 A YU 80293A YU 49060 B YU49060 B YU 49060B
Authority
YU
Yugoslavia
Prior art keywords
heteroaryl
lower alkyl
inhibitor
nr10r11
sum
Prior art date
Application number
YU80293A
Other languages
English (en)
Serbo-Croatian (sh)
Other versions
YU80293A (sh
Inventor
R. Harry Davis
Original Assignee
Schering Corporation 2000
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation 2000 filed Critical Schering Corporation 2000
Publication of YU80293A publication Critical patent/YU80293A/sh
Publication of YU49060B publication Critical patent/YU49060B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
YU80293A 1992-12-23 1993-12-21 FARMACEUTSKE KOMPOZICIJE KOJE SADRŽE INHIBITOR BIOSINTEZE HOLESTEROLA I INHIBITIR APSORPCIJE Гџ-LAKTAM HOLESTEROLA YU49060B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99548892A 1992-12-23 1992-12-23

Publications (2)

Publication Number Publication Date
YU80293A YU80293A (sh) 1997-12-05
YU49060B true YU49060B (sh) 2003-08-29

Family

ID=25541876

Family Applications (1)

Application Number Title Priority Date Filing Date
YU80293A YU49060B (sh) 1992-12-23 1993-12-21 FARMACEUTSKE KOMPOZICIJE KOJE SADRŽE INHIBITOR BIOSINTEZE HOLESTEROLA I INHIBITIR APSORPCIJE Гџ-LAKTAM HOLESTEROLA

Country Status (32)

Country Link
US (1) US5661145A (https=)
EP (1) EP0675714B1 (https=)
JP (1) JP3992728B2 (https=)
KR (1) KR100306936B1 (https=)
CN (1) CN1090479C (https=)
AT (1) ATE175872T1 (https=)
AU (1) AU680864B2 (https=)
CA (1) CA2152351C (https=)
CZ (1) CZ287125B6 (https=)
DE (1) DE69323213T2 (https=)
DK (1) DK0675714T3 (https=)
EE (1) EE03383B1 (https=)
ES (1) ES2128552T3 (https=)
FI (1) FI952916L (https=)
GR (1) GR3029405T3 (https=)
HR (1) HRP931515B1 (https=)
HU (1) HU221724B1 (https=)
IL (1) IL108112A (https=)
LT (1) LT3300B (https=)
LV (1) LV10919B (https=)
MX (1) MX9308053A (https=)
MY (1) MY109538A (https=)
NO (1) NO311325B1 (https=)
NZ (1) NZ259790A (https=)
PL (1) PL174128B1 (https=)
SG (1) SG45147A1 (https=)
SI (1) SI9300677A (https=)
SK (1) SK281173B6 (https=)
TW (1) TW319698B (https=)
WO (1) WO1994014433A1 (https=)
YU (1) YU49060B (https=)
ZA (1) ZA939552B (https=)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU2453295A (en) * 1994-09-20 1996-04-19 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
AU720853B2 (en) 1995-11-02 2000-06-15 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
AR023463A1 (es) 1999-04-16 2002-09-04 Schering Corp Uso de compuestos de azetidinona
EP1192963A4 (en) * 2000-04-05 2004-08-25 Toray Industries ADSORBENTS FOR PROTEINS OF THE HIGH MOBILITY PROTEIN AND PILLAR GROUP FOR CLEANING BODY LIQUIDS
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
CN101297969B (zh) * 2001-01-26 2011-03-09 先灵公司 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药
DK1373230T3 (da) 2001-03-28 2005-11-07 Schering Corp Enantiselektiv syntese af azetidinon mellemprodukter
JP2005504091A (ja) * 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AU2002335770B2 (en) * 2001-09-21 2005-08-18 Merck Sharp & Dohme Corp. Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
AU2002348276A1 (en) 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
EP1810971B1 (en) * 2003-03-07 2013-12-25 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP4589919B2 (ja) * 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CA2517571C (en) * 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
GB2423927A (en) * 2003-08-29 2006-09-13 Cotherix Inc Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
AU2004308332B2 (en) * 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
JP4590417B2 (ja) * 2004-01-16 2010-12-01 メルク・シャープ・エンド・ドーム・コーポレイション Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法
EP3269713A1 (en) * 2004-07-01 2018-01-17 OPKO Health, Inc. Piperidine derivatives as nk1 antagonists
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076569A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
EP1846410B1 (en) 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
TW200738676A (en) * 2005-06-20 2007-10-16 Schering Corp Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR057072A1 (es) * 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
AU2006331770A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US7910698B2 (en) * 2006-02-24 2011-03-22 Schering Corporation NPC1L1 orthologues
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
JP2010514841A (ja) * 2007-01-03 2010-05-06 グレン ブイ． コルネット， 肺疾患および心疾患の処置におけるシクレタニンおよびｐｋｃ阻害剤
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
MX2011009852A (es) 2009-03-27 2011-09-29 Bristol Myers Squibb Co Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
EP2892896B1 (en) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
US9499482B2 (en) 2012-09-05 2016-11-22 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
MA53175A (fr) 2018-07-19 2021-05-26 Astrazeneca Ab Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
AU2022291768A1 (en) 2021-06-16 2023-11-30 Celgene Corporation Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5085473A (en) * 1990-10-09 1992-02-04 Yuhe Yang Air actuated car curtain device
JP2525125B2 (ja) 1991-07-23 1996-08-14 シェリング・コーポレーション 血清コレステロ―ル低下薬として有用な置換β−ラクタム化合物およびそれらの製法
PT2807099T (pt) 2012-01-26 2017-02-08 Intralot Sa Integrated Lottery Systems & Services Métodos e sistemas para dispensa e tiragem

Also Published As

Publication number Publication date
IL108112A (en) 1999-11-30
FI952916A7 (fi) 1995-06-14
CN1095591A (zh) 1994-11-30
FI952916A0 (fi) 1995-06-14
JPH08505141A (ja) 1996-06-04
DK0675714T3 (da) 1999-09-13
CZ287125B6 (en) 2000-09-13
EE9400341A (et) 1996-04-15
JP3992728B2 (ja) 2007-10-17
ATE175872T1 (de) 1999-02-15
MX9308053A (es) 1994-06-30
NO311325B1 (no) 2001-11-19
PL174128B1 (pl) 1998-06-30
CN1090479C (zh) 2002-09-11
TW319698B (https=) 1997-11-11
ZA939552B (en) 1994-10-12
HRP931515A2 (en) 1996-12-31
LT3300B (en) 1995-06-26
GR3029405T3 (en) 1999-05-28
IL108112A0 (en) 1994-04-12
NZ259790A (en) 1997-02-24
NO952529L (no) 1995-06-23
US5661145A (en) 1997-08-26
HU9501854D0 (en) 1995-08-28
LTIP1514A (en) 1994-10-25
AU680864B2 (en) 1997-08-14
LV10919B (en) 1996-04-20
SI9300677A (en) 1994-09-30
DE69323213D1 (de) 1999-03-04
CA2152351A1 (en) 1994-07-07
AU5872094A (en) 1994-07-19
EE03383B1 (et) 2001-04-16
PL309636A1 (en) 1995-10-30
HU221724B1 (hu) 2002-12-28
NO952529D0 (no) 1995-06-23
ES2128552T3 (es) 1999-05-16
HUT72081A (en) 1996-03-28
FI952916L (fi) 1995-06-14
SK78395A3 (en) 1996-05-08
HRP931515B1 (en) 2000-02-29
CA2152351C (en) 2009-09-22
YU80293A (sh) 1997-12-05
WO1994014433A1 (en) 1994-07-07
SK281173B6 (sk) 2000-12-11
EP0675714A1 (en) 1995-10-11
DE69323213T2 (de) 1999-07-08
SG45147A1 (en) 1998-01-16
KR100306936B1 (ko) 2001-11-30
MY109538A (en) 1997-02-28
EP0675714B1 (en) 1999-01-20
CZ164395A3 (en) 1996-03-13
LV10919A (lv) 1995-12-20

Similar Documents

Publication Publication Date Title
YU49060B (sh) FARMACEUTSKE KOMPOZICIJE KOJE SADRŽE INHIBITOR BIOSINTEZE HOLESTEROLA I INHIBITIR APSORPCIJE Гџ-LAKTAM HOLESTEROLA
EP1393729A3 (en) Combination chemotherapy involving topotecan and a platinum coordination compound
BG103518A (en) 2-(purin-9-yl)tetrahydrofuran-3,4-diol derivatives
CZ89995A3 (en) O-alkylated derivatives of rapamycin, pharmaceutical preparation and their use, particularly as immunosuppressives
AU5873998A (en) Quinazolinone compounds
BG103947A (en) Derivatives of 9-oxymerythromycin
EP0902789A4 (https=)
AU8054287A (en) Transdermal flux enhancing compositions
UA27899C2 (uk) Порошкова антибактеріальна композиція, що призначена для орального використання, яка містить гідратований цефтибутен
AU8670891A (en) Pharmaceutical compositions active in the therapy of neurological affections in aids patients, containing as an active principle at least one compound selected from the group consisting of S-adenosyl-L-methionine salt, 5-methyl- tetrahydrofolic acid, 5-formyltetrahydrofolic acid
NZ318282A (en) Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
EP0725641A4 (https=)
TW221378B (https=)
HUP9901794A2 (hu) Protonpumpa inhibitorok új beadási formája
EP0192210A3 (en) New cephem compounds and processes for preparation thereof
ES8506622A1 (es) Procedimiento para preparar analogos de mevalono-lactona y derivados de los mismos
ATE289506T1 (de) Hemmung der tnf-aktivität mit zusammensetzungen enthaltend heparin und lösliche tnf rezeptoren
DE60005469D1 (de) Arzneizusammensetzung enthaltend Ascorbinsäure und Pektin
HUP9802348A2 (hu) 2-Fenil-3-aroil-benzotiofének alkalmazása plazminogén aktivátor inhibitor-1 gátló hatású gyógyszerkészítmények előállítására
CA2228524A1 (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating human malignancies
IL111138A (en) Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia
DE3777926D1 (de) Neue synergistische kombination bestehend aus einem phosphodiesterase-hemmer und einem tromboxan-a2-antagonisten und deren verwendung bzw. herstellung.
ATE101150T1 (de) Thiophen-2-carboxamid-derivate und ihre verwendung als pharmazeutische mittel.
JPS6442428A (en) Antimalarial agent